Cumulative Gross Losses and Impairments
Merck & Co. Cumulative Gross Losses and Impairments remained flat by 0.0% to $531.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $531.00M to $531.00M. Over 5 years (FY 2020 to FY 2025), Cumulative Gross Losses and Impairments shows relatively stable performance with a 0.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A rising trend indicates persistent underperformance or market-wide stress affecting the firm's long-term holdings.
Detailed definition
This metric aggregates all unrealized losses and impairment charges on investments that have not yet been recognized in...
Peer comparison
Reported in equity or comprehensive income disclosures for firms with significant investment portfolios.
cumulative_gross_losses_and_impairmentsHistorical Data
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $531.00M | $531.00M | $531.00M | $531.00M | $531.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
Cumulative Gross Losses and Impairments at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s cumulative gross losses and impairments?
- Merck & Co. (MRK) reported cumulative gross losses and impairments of $531.00M in Q4 2025.
- How has Merck & Co.'s cumulative gross losses and impairments changed year-over-year?
- Merck & Co.'s cumulative gross losses and impairments decreased by 0.0% year-over-year, from $531.00M to $531.00M.
- What is the long-term trend for Merck & Co.'s cumulative gross losses and impairments?
- Over 5 years (2020 to 2025), Merck & Co.'s cumulative gross losses and impairments has grown at a 0.0% compound annual growth rate (CAGR), from $531.00M to $531.00M.
- What does cumulative gross losses and impairments mean?
- The total amount of value lost on investments that hasn't been officially recorded as a loss on the income statement yet.